• In 2012, there were an estimated 98,400 people living with human immunodefi ciency virus (HIV) in the United Kingdom (UK).
Note: Regimen failure is defi ned as virologic failure or discontinuation of fi rst-line therapy due to tolerability or other reasons.
Model Analyses
• Two analyses were conducted: -Full population (primary analysis) -Population with low baseline viral load (< 100,000 copies/ mL) (secondary analysis)
• Probabilistic sensitivity analyses and scenario analyses were conducted to determine whether results were sensitive to model inputs.
• Because therapeutic tenders are commonplace in the UK, price reduction scenarios at various levels were conducted for illustrative purposes.
• Results are shown for the primary analysis only, unless otherwise indicated.
Input Parameters
• Head-to-head regimen effi cacy data were available for up to 192 weeks for participants with low baseline viral load and up to 108 weeks for participants with high baseline viral load (due to early trial termination in this subgroup).
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-Kaplan-Meier survival estimates for time to regimen failure ( Figure 2 ) were used to estimate annual probabilities of switching off fi rst-line therapies by fi tting exponential curves to the data.
-Changes in CD4 cell count (means and standard deviations [SDs]) (Table 1) were used to estimate annual transition probabilities. 
RESULTS

Primary and Secondary Analysis Results
• In both analyses, individuals using TDF/FTC-based regimens remained on fi rst-line therapy longer ( Figure 3 ) and accrued more QALYs (Table 3 ) than individuals using ABC/3TC-based regimens.
• TDF/FTC + EFV had the lowest projected average cost per year on fi rst-line therapy (£12,902 vs. £13,087-£14,488).
• Over the duration of fi rst-line therapy, TDF/FTC-based regimens were cost-effective compared with ABC/3TC-based regimens, using a willingness-to-pay threshold of £30,000 per QALY gained (Table 3 ). 
Sensitivity and Scenario Analysis Results
• Probabilistic sensitivity analysis results indicated that TDF/ FTC-based regimens were optimal at willingness-to-pay thresholds between approximately £20,000 and £100,000 per QALY gained.
• Results of the analysis were robust in scenarios that tested discount rate, time horizon, and antiretroviral drug prices that refl ect the UK market (Table 4) . 
LIMITATIONS
• Modeled fi rst-line regimens and patient characteristics were based on the ACTG 5202 clinical trial, which included United States participants only.
• The analysis evaluated outcomes for patients while on fi rst-line therapy only.
• Individuals could switch therapy due to virologic failure or other reasons, including treatment-related adverse events. However, this analysis considered only costs related to switching and did not consider other costs or utility decrements associated with adverse events; therefore, this analysis offers a conservative estimate of the costeffectiveness of TDF/FTC-based regimens because of the improved safety profi le of TDF/FTC compared with ABC/3TC.
DISCUSSION AND CONCLUSIONS
• In an analysis of the regimens examined in ACTG 5202, TDF/ FTC-based regimens yielded more favorable health outcomes and were predicted to be cost-effective compared with ABC/3TC-based regimens in treatment-naïve adults with HIV-1 infection in the UK.
• TDF/FTC-based regimens remained cost-effective even when price discounts for ABC/3TC-based regimens were considered.
• Further analyses are needed using mixed-treatment comparisons and a systematic review of available trial data to further assess the cost-effectiveness of all preferred fi rstline and subsequent regimens in the UK.
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• Costs for switching regimens due to virologic failure (£817.82) and tolerability/other reasons (£355.51) were based on physician visits and laboratory tests.
• Annual medical care costs, utility values, and HIV-related mortality rates were stratifi ed by CD4 cell-count range ( Table 2 ).
• Age-and gender-specifi c general population mortality was adjusted by a relative risk factor of 1.5 to account for higher non-HIV-related mortality in people with HIV.
